Role of Brahma-Related Gene 1 (Brg1) in Heart Disease

0
0
0

Role of Brahma-Related Gene 1 (Brg1) in Heart Disease

Heart disease is the leading cause of death worldwide, claiming 17.9 million lives annually according to the World Health Organization. Behind many cases of heart damage—from thickened heart muscle to life-threatening aneurysms—lies a tiny but powerful protein: Brahma-related gene 1 (Brg1). As a key part of the SWI/SNF chromatin-remodeling complex, Brg1 uses energy from breaking down ATP to control how genes are turned on or off, repair DNA, and copy genetic material. Recent research has uncovered its critical role in heart disease, linking it to inflammation, cell death, and the structural changes that weaken the heart.

This perspective was written by Wen-Bo Huang, Wen-Yang Liu, and Gui-Ling Xie from the Department of Anesthesiology at Heyuan People’s Hospital in Guangdong, China, and published in the Chinese Medical Journal in 2021. It synthesizes findings from dozens of studies to explain how Brg1 shapes heart health—and disease.

What Is Brg1? A Quick Primer

Brg1 is a large protein (over 1,600 amino acids) with multiple “domains” that act like molecular tools:

  • The QLQ domain helps Brg1 bind to other proteins.
  • The HSA domain interacts with DNA-binding proteins.
  • The bromodomain recognizes chemical tags on histones (the proteins that package DNA), allowing Brg1 to “read” which genes should be active.

Together, these domains let Brg1 remodel chromatin—adjusting how DNA is wrapped around histones—to either turn on (activate) or silence (repressed) genes. For example, Brg1 can team up with proteins like histone deacetylases (HDACs) to quiet genes or work with transcription factors to boost them.

Brg1 and Cardiac Hypertrophy: Thickening the Heart Muscle

When the heart is stressed (e.g., from high blood pressure or heart attack), it often responds by thickening its muscle—a condition called cardiac hypertrophy. Over time, this makes the heart stiffer and less able to pump blood. Brg1 is a major driver here.

Studies show that Brg1 becomes overactive in stressed heart cells. For instance:

  • It forms complexes with FoxM1 (a protein that controls cell growth) in heart muscle and blood vessel cells to trigger harmful thickening.
  • It works with HDACs and poly(ADP-ribose) polymerase (PARP) to switch genes that build heart muscle: swapping α-MHC (a fast-contracting protein) for β-MHC (a slow, less efficient one). This swap is a hallmark of hypertrophied hearts.

The good news? When researchers “knock out” (remove) Brg1 in lab models, the α-MHC to β-MHC switch stops—and heart muscle thickening eases. Brg1 also affects genes like endothelin 1 (a molecule that constricts blood vessels); blocking Brg1 reduces its activity, further slowing hypertrophy.

Aortic Aneurysms: Brg1 Controls Smooth Muscle Cells

Aortic aneurysms—weakened, bulging blood vessels in the main artery from the heart—start when smooth muscle cells in the artery wall lose their normal function. Brg1 is key to this process.

In people with thoracic aortic aneurysms (aneurysms in the upper aorta), Brg1 levels are much higher than in healthy individuals. Why? Brg1 regulates genes that control smooth muscle cell “phenotype”—whether they act like contractile cells (normal) or repair cells (abnormal). It does this by:

  • Binding to microRNA promoters to remodel chromatin and change cell behavior.
  • Controlling long non-coding RNAs (like HIF1A-AS1) that affect cell growth and death.
  • Activating matrix metalloproteinases (MMP2 and MMP9)—enzymes that break down the artery’s structural proteins, weakening the wall.

Heart Failure: Brg1 Rewires Gene Activity

Heart failure happens when the heart can’t pump enough blood. Brg1 contributes by reprogramming genes that control heart development and function.

For example:

  • Brg1 binds to the ADAMTS1 gene (which makes a protein that limits blood vessel growth) to keep it silenced. If this balance is off, heart muscle (myocardium) grows too much or too little—both leading to failure.
  • In mice missing Brg1 (and its cousin Brm), heart function collapses because genes that control contraction and electrical signaling go haywire.

Brg1 also interacts with critical heart transcription factors like Tbx5, Tbx20, and NKX2-5. When their balance is disrupted, severe heart defects follow.

Diabetes and Heart Disease: Brg1 Links Metabolism to Damage

Type 2 diabetes doubles the risk of heart disease, including diabetic cardiomyopathy (heart muscle damage from high blood sugar). Brg1 plays a unique role here.

High glucose levels (hyperglycemia) impair Brg1’s ability to work with Nrf2—a protein that defends cells from oxidative stress. Normally, Brg1 helps Nrf2 turn on protective genes like HO-1 (makes an antioxidant enzyme) and STAT3 (reduces inflammation). But in diabetes, this pathway breaks down:

  • Brg1 can’t help Nrf2 form “Z-DNA” (a twisted DNA shape that attracts gene-reading proteins like RNA polymerase II).
  • Protective gene activity drops, and inflammation and oxidative stress rise—damaging heart cells.

Brg1 also fuels atherosclerosis (artery-clogging plaque) by activating adhesion molecules (like ICAM-1) on blood vessel cells, which attract inflammatory cells.

Ischemia-Reperfusion Injury: The Controversial Role of Brg1

When doctors restore blood flow to a blocked coronary artery (reperfusion), they save lives—but sometimes cause ischemia-reperfusion injury (MIRI): damage from sudden oxygen and nutrient rush. Brg1’s role here is tricky.

Some studies say Brg1 helps:

  • In zebrafish, Brg1 teams up with a methyltransferase (Dnmt3ab) to silence cdkn1c (a gene that stops cell growth), boosting heart regeneration.
  • It helps Nrf2 turn on HO-1 and STAT3 to reduce MIRI in healthy hearts.

But other research finds Brg1 harms:

  • It works with a demethylase (KDM3A) to turn on NOX (a gene that makes reactive oxygen species, or “cell poisons”), increasing damage.
  • Knocking out Brg1 in blood vessel cells reduces adhesion molecules and neutrophil (immune cell) infiltration—cutting MIRI severity.

Why the conflict? It likely depends on the cell type (e.g., heart muscle vs. blood vessels) or experimental conditions. More research is needed to untangle this.

Brg1: A Future Target for Heart Disease?

The takeaway? Brg1 is a double-edged sword in heart disease. It can protect or harm, depending on where, when, and how it’s active. But its role in gene regulation—activating, silencing, and interacting with heart-specific proteins—makes it a promising target for new therapies.

For example:

  • Drugs that block Brg1’s overactivity could slow hypertrophy or aneurysm growth.
  • Treatments that boost Brg1’s protective effects (e.g., with Nrf2) might help diabetic or reperfused hearts.

But there’s a catch: Brg1 is active in many organs (brain, immune system, etc.). Targeting it specifically in the heart will be key to avoiding side effects.

As the authors note, “Understanding the effects of Brg1 regulation during heart disease requires further basic and clinical studies.” But for a protein that touches so many parts of heart health, Brg1 is definitely one to watch.

References (original study citations):

  1. Xiao C, et al. Chromatin-remodelling factor Brg1 regulates myocardial proliferation and regeneration in zebrafish. Nature Communications 2016;7:13787. doi.org/10.1038/ncomms13787
  2. Li H, et al. Adiponectin ameliorates hyperglycemia-induced cardiac hypertrophy and dysfunction by concomitantly activating Nrf2 and Brg1. Free Radical Biology and Medicine 2015;84:311–321. doi.org/10.1016/j.freeradbiomed.2015.03.007
  3. Trotter KW, et al. The HSA domain of Brg1 mediates critical interactions required for glucocorticoid receptor-dependent transcriptional activation in vivo. Molecular and Cellular Biology 2008;28:1413–1426. doi.org/10.1128/MCB.01301-07
  4. Trotter KW, et al. Glucocorticoid receptor transcriptional activation via the BRG1-dependent recruitment of TOP2b and Ku70/86. Molecular and Cellular Biology 2015;16:2799–2817. doi.org/10.1128/MCB.00230-15
  5. Allen MD, et al. Solution structure of the BRK domains from CHD7. Journal of Molecular Biology 2007;371:1135–1140. doi.org/10.1016/j.jmb.2007.06.007
  6. Pal S, et al. mSin3A/histone deacetylase 2- and PRMT5-containing Brg1 complex is involved in transcriptional repression of the Myc target gene cad. Molecular and Cellular Biology 2003;23:7475–7487. doi.org/10.1128/mcb.23.21.7475-7487.2003
  7. Yang J, et al. Pathological Ace2-to-Ace enzyme switch in the stressed heart is transcriptionally controlled by the endothelial Brg1-FoxM1 complex. Proceedings of the National Academy of Sciences 2016;113:E5628–E5635. doi.org/10.1073/pnas.1525078113
  8. Chang C, Han P. Epigenetic and lncRNA regulation of cardiac pathophysiology. Biochimica et Biophysica Acta 2016;1863:1767–1771. doi.org/10.1016/j.bbamcr.2016.03.005
  9. Weng X, et al. A crosstalk between chromatin remodeling and histone H3K4 methyltransferase complexes in endothelial cells regulates angiotensin II-induced cardiac hypertrophy. Journal of Molecular and Cellular Cardiology 2015;82:48–58. doi.org/10.1016/j.yjmcc.2015.02.010
  10. Zhang H, et al. MiR-139-5p inhibits proliferation and promoted apoptosis of human airway smooth muscle cells by downregulating the Brg1 gene. Respiratory Physiology & Neurobiology 2017;246:9–16. doi.org/10.1016/j.resp.2017.07.004
  11. Wang S, et al. Brg1 expression is increased in thoracic aortic aneurysms and regulates proliferation and apoptosis of vascular smooth muscle cells through the long non-coding RNA HIF1A-AS1 in vitro. European Journal of Cardio-Thoracic Surgery 2015;47:439–446. doi.org/10.1093/ejcts/ezu215
  12. Xu W, et al. MKL1 links epigenetic activation of MMP2 to ovarian cancer cell migration and invasion. Biochemical and Biophysical Research Communications 2017;487:500–508. doi.org/10.1016/j.bbrc.2017.04.006
  13. Hota SK, Benoit G. ATP-dependent chromatin remodeling during mammalian development. Development 2016;143:2882–2897. doi.org/10.1242/dev.128892
  14. Willis MS, et al. BRG1 and BRM function antagonistically with c-MYC in adult cardiomyocytes to regulate conduction and contractility. Journal of Molecular and Cellular Cardiology 2017;105:99–109. doi.org/10.1016/j.yjmcc.2017.02.003
  15. Fang F, et al. Proinflammatory stimuli engage Brahma related gene 1 and Brahma in endothelial injury. Circulation Research 2013;113:986–996. doi.org/10.1161/CIRCRESAHA.113.301296
  16. Wang Y, et al. Cardioprotection from emulsified isoflurane postconditioning is lost in rats with streptozotocin-induced diabetes due to the impairment of Brg1/Nrf2/STAT3 signalling. Clinical Science 2016;130:801–812. doi.org/10.1042/CS20150617
  17. Liu Y, et al. Effect of autophagy inhibition on the protection of ischemia preconditioning against myocardial ischemia/reperfusion injury in diabetic rats. Chinese Medical Journal 2018;131:1702–1709. doi.org/10.4103/0366-6999.235867
  18. Gao S, et al. Diabetes blocks the cardioprotective effects of sevoflurane postconditioning by impairing Nrf2/Brg1/HO-1 signaling. European Journal of Pharmacology 2016;779:111–121. doi.org/10.1016/j.ejphar.2016.03.018
  19. Li Z, et al. Brg1 regulates NOX gene transcription in endothelial cells and contributes to cardiac ischemia-reperfusion injury. Biochimica et Biophysica Acta 2018;1864:3477–3486. doi.org/10.1016/j.bbadis.2018.08.002
  20. Zhang X, et al. Brg1 deficiency in vascular endothelial cells blocks neutrophil recruitment and ameliorates cardiac ischemia-reperfusion injury in mice. International Journal of Cardiology 2018;269:250–258. doi.org/10.1016/j.ijcard.2018.07.105

This article is based on a perspective by Huang WB, Liu WY, Xie GL published in the Chinese Medical Journal (2021;134(9):1061–1063). doi.org/10.1097/CM9.0000000000001480

Was this helpful?

0 / 0